414 related articles for article (PubMed ID: 25779572)
41. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein.
Mercorelli B; Luganini A; Celegato M; Palù G; Gribaudo G; Loregian A
Antiviral Res; 2018 Feb; 150():130-136. PubMed ID: 29274844
[TBL] [Abstract][Full Text] [Related]
42. Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs).
Wild M; Kicuntod J; Seyler L; Wangen C; Bertzbach LD; Conradie AM; Kaufer BB; Wagner S; Michel D; Eickhoff J; Tsogoeva SB; Bäuerle T; Hahn F; Marschall M
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430060
[TBL] [Abstract][Full Text] [Related]
43. The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.
Oiknine-Djian E; Weisblum Y; Panet A; Wong HN; Haynes RK; Wolf DG
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712656
[TBL] [Abstract][Full Text] [Related]
44. Drug targets in cytomegalovirus infection.
Andrei G; De Clercq E; Snoeck R
Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
[TBL] [Abstract][Full Text] [Related]
45.
Ghassabian H; Falchi F; Timmoneri M; Mercorelli B; Loregian A; Palù G; Alvisi G
Viruses; 2021 May; 13(5):. PubMed ID: 34065234
[TBL] [Abstract][Full Text] [Related]
46. De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.
Jo H; Kwon DE; Han SH; Min SY; Hong YM; Lim BJ; Lee KH; Jo JH
J Infect Dis; 2020 Apr; 221(9):1480-1487. PubMed ID: 31802131
[TBL] [Abstract][Full Text] [Related]
47. The human cytomegalovirus terminase complex as an antiviral target: a close-up view.
Ligat G; Cazal R; Hantz S; Alain S
FEMS Microbiol Rev; 2018 Mar; 42(2):137-145. PubMed ID: 29361041
[TBL] [Abstract][Full Text] [Related]
48. Letermovir: First Global Approval.
Kim ES
Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
[TBL] [Abstract][Full Text] [Related]
49. The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication.
Zhang H; Niu X; Qian Z; Qian J; Xuan B
J Med Virol; 2015 Dec; 87(12):2135-44. PubMed ID: 26058558
[TBL] [Abstract][Full Text] [Related]
50. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
51. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
52. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
53. Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.
Chou S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6588-93. PubMed ID: 26259791
[TBL] [Abstract][Full Text] [Related]
54. Anti-CMV therapy, what next? A systematic review.
Gourin C; Alain S; Hantz S
Front Microbiol; 2023; 14():1321116. PubMed ID: 38053548
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, and evaluation of WC5 analogues as inhibitors of human cytomegalovirus Immediate-Early 2 protein, a promising target for anti-HCMV treatment.
Massari S; Mercorelli B; Sancineto L; Sabatini S; Cecchetti V; Gribaudo G; Palù G; Pannecouque C; Loregian A; Tabarrini O
ChemMedChem; 2013 Aug; 8(8):1403-14. PubMed ID: 23757191
[TBL] [Abstract][Full Text] [Related]
56. Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication.
Cotin S; Calliste CA; Mazeron MC; Hantz S; Duroux JL; Rawlinson WD; Ploy MC; Alain S
Antiviral Res; 2012 Nov; 96(2):181-6. PubMed ID: 23000494
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
[TBL] [Abstract][Full Text] [Related]
58. Approaches for the generation of new anti-cytomegalovirus agents: identification of protein-protein interaction inhibitors and compounds against the HCMV IE2 protein.
Mercorelli B; Gribaudo G; Palù G; Loregian A
Methods Mol Biol; 2014; 1119():349-63. PubMed ID: 24639231
[TBL] [Abstract][Full Text] [Related]
59. Human cytomegalovirus DNA replication: antiviral targets and drugs.
Mercorelli B; Sinigalia E; Loregian A; Palù G
Rev Med Virol; 2008; 18(3):177-210. PubMed ID: 18027349
[TBL] [Abstract][Full Text] [Related]
60. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.
Kaptein SJ; Efferth T; Leis M; Rechter S; Auerochs S; Kalmer M; Bruggeman CA; Vink C; Stamminger T; Marschall M
Antiviral Res; 2006 Feb; 69(2):60-9. PubMed ID: 16325931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
